Cancer Immunology Immunotherapy

Article	Citations
Chemotherapy: a double-edged sword in cancer treatment	123
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis	107
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma	100
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study	65
Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma	61
Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma	56
Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer	51
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors	49
Regulatory T cells promote glioma cell stemness through TGF-β–NF-κB–IL6–STAT3 signaling	49
Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab	49
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial	46
Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome	44
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer	44
ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas	42
Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers	42
Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer	42
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis	41
CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration	40
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncol	40
Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models	39
In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes	39
LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2	39
TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer	38
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China	37
Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis	37

Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials	36
Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions	35
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors	35
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors	35
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression	35
Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis	35
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma	33
CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors	33
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma	33
The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer	32
Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment	32
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte	32
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells	32
Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab	32
Interleukin-12 as an in situ cancer vaccine component: a review	31
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL	31
Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodi	30
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors	30
The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer	30
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy	29
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer	29
Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies	29
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients	28
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC	28
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape	28
Prognostic role of the systemic immune–inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration	28
Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC	28
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia	27
Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice	27
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors	27
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study o	27
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma	27
Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values	27
Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy	27
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study	27
Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies	26
Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma	26
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience	26
Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway	26
Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18	25
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR	25
Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study	25
Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment	25
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells	25
The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma	24
Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy	24
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors	24
miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis	24
Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab	24
Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer	23

Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TA	23
Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer	23
LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway	23
Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment	23
CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer	23
Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma	22
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody	22
Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10	22
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study	22
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)	22
Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells	22
Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations	22
Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis	22
Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma	22
CD74+ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma	22
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma	22
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study	21
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations	21
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade	21
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient	21
Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas	21
Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer	21
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients	21
Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports	21
Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer	20
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review	20
Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma	20
Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma	20
Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment	20
CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy	20
APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application	20
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used	20
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIM	20
The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-rela	20
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors	19
Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient	19
Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration	19
Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy	19
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study	19
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature	19
Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients	19
Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis	19
The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, re	19
Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint	19
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model	19
Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody	18
Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma	18
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis	18
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer	18
Functional virus-specific memory T cells survey glioblastoma	18
PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures	18
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer	18
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21	18
A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer	17
Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma	17
Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance	17
The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells	17
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature	17
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors	17
Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1	17
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer	17
Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden	17
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy	17
A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy	17
TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism	17
IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity	17
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?	17
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters	17
Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL	17
CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma	17
CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer	17
Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma	17
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186	17
Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy	16
Metabolic profiles of regulatory T cells in the tumour microenvironment	16
Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy	16
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial	16
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies	16
Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells	16
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma	16

Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients	16
Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq	16
Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma	16
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer	16
Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes	16
Immune epitopes identification and designing of a multi-epitope vaccine against bovine leukemia virus: a molecular dynamics and immune simulation approaches	16
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis	16
Parvimonas micra is associated with tumour immune profiles in molecular subtypes of colorectal cancer	16
Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis	16
Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program	16
Evaluation of cytokines in the tumor microenvironment of lung cancer using bronchoalveolar lavage fluid analysis	16
PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung	15
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses	15
Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells	15
Platelet-expressed immune checkpoint regulator GITRL in breast cancer	15
HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study	15
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma	15
Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma	15
PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients	14
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease	14
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody	14
The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?	14
Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection	14
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group	14
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2	14
CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer	14
IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas	14
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy	14
Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer	14
Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study	14
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes	14
Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer	14
Inflammasome activation, NLRP3 engagement and macrophage recruitment to tumor microenvironment are all required for Salmonella antitumor effect	14
Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function	14
The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor	14
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit	14
Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery	14
High abundance of Lachnospiraceae in the human gut microbiome is related to high immunoscores in advanced colorectal cancer	14
Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer	14
Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma	14
The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors	13
Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation	13
SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma	13
IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors	13
The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer	13
Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colore	13
The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with diffuse large B cell lymphoma (DLBCL)	13
Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy	13
SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells	13
TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer	13
Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma	13
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival	13
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors	13
Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment	13
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial	13
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation	13
Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells	13
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and m	13